Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Health Partners Institute

Neither a doctor nor a teaching hospital

Research payments

$1,468,465

185 payments

Through program year 2025, Health Partners Institute is reported as receiving $1,468,465 in research payments, across 185 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $162,190 26
2024 Research $399,256 37
2023 Research $114,060 19
2022 Research $186,828 26
2021 Research $231,984 16
2020 Research $141,721 27
2019 Research $232,425 34

Breakdown

Who paid Research payments · program years 2019–2025
  1. Clovis Oncology, Inc. $469,515 24 payments
  2. AbbVie, Inc. $295,975 35 payments
  3. Novartis Pharmaceuticals Corporation $189,449 9 payments
  4. pharmaand GmbH $107,176 18 payments
  5. Pfizer Inc. $98,850 14 payments
  6. Genentech, Inc. $90,286 28 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $88,821 6 payments
  8. Napo Pharmaceuticals Inc $42,981 14 payments
  9. Novocure Inc. $33,400 3 payments
  10. Merck Sharp & Dohme Corporation $19,335 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) $576,691 42 payments
  2. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $204,513 24 payments
  3. A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features $90,850 11 payments
  4. A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - MM Study $88,821 6 payments
  5. A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $57,589 2 payments
  6. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $53,741 2 payments
  7. A Phase 3 Multicenter, Randomized, Double Blind Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted-Cancer Therapies with or without Standar Chemotherapy $42,981 14 payments
  8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $34,479 2 payments
  9. EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. $33,400 3 payments
  10. Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Prescribed Alpelisib $33,339 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record